Enveric Biosciences (ENVB) Cash from Operations (2010 - 2026)
Enveric Biosciences (ENVB) posted Cash from Operations of 2256839.0 for Q1 2026, down 26.44% sequentially from 1784863.0 in Q4 2025, and up 5.63% YoY from 2136469.19 in Q1 2025.
Enveric Biosciences (ENVB) Cash from Operations (2010 - 2026) Analysis & Trends
Enveric Biosciences has reported Cash from Operations for 17 years, with the latest figure at 2256839.0 in Q1 2026.
- Quarterly Cash from Operations rose 5.63% year-over-year to 2256839.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 8006800.0 (down 6.48% YoY) and the FY2025 annual result came in at 8141543.0, down 5.38% from the prior year.
- Cash from Operations retreated to 2256839.0 in Q1 2026 per ENVB's latest filing, from 1784863.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 927070.0 in Q3 2024 and troughed at 5137009.0 in Q1 2023.
- A 5-year average of 2903862.06 and a median of 2598347.0 in 2024 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2022 and 2024: Cash from Operations tumbled 126.78% in 2022, then jumped 66.17% in 2024.
- Over 5 years, Cash from Operations stood at 3462117.0 in 2022, then jumped by 49.42% to 1751048.0 in 2023, then advanced by 25.1% to 1311549.0 in 2024, then plunged by 36.09% to 1784863.0 in 2025, then slipped by 26.44% to 2256839.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 2256839.0, 1784863.0, and 2074956.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.39 Bn | 132.54 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 86.47 Bn | 78.47 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 65.25 Bn | 60.07 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.79 Bn | 56.66 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 42.27 Bn | 37.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.17 Bn | 27.86 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.61 Bn | 10.22 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.46 Bn | - | 728.46 Mn |
| 10 | Enveric Biosciences | 5.58 Mn | -2.71 Mn | - | -2.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.26 Mn |
| Mar 31, 2026 | -2.26 Mn |
| Dec 31, 2025 | -1.78 Mn |
| Dec 31, 2025 | -1.78 Mn |
| Sep 30, 2025 | -2.07 Mn |
| Sep 30, 2025 | -2.07 Mn |
| Jun 30, 2025 | -1.89 Mn |
| Jun 30, 2025 | -1.89 Mn |
| Mar 31, 2025 | -2.39 Mn |
| Mar 31, 2025 | -2.39 Mn |
| Dec 31, 2024 | -1.31 Mn |
| Dec 31, 2024 | -1.31 Mn |
| Sep 30, 2024 | -927,070.00 |
| Sep 30, 2024 | -927,070.00 |
| Jun 30, 2024 | -2.89 Mn |
| Jun 30, 2024 | -2.89 Mn |
| Mar 31, 2024 | -2.60 Mn |
| Mar 31, 2024 | -2.60 Mn |
| Dec 31, 2023 | -1.75 Mn |
| Dec 31, 2023 | -1.75 Mn |